The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559 · cited 3×
“VEGFA has high affinity to VEGFR2 expressed in endothelial cells.”
BackgroundRole of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“Now several VEGF(R)-targeted agents are approved or undergoing clinical application for treatment such as bevacizumab, a VEGF-neutralizing monoclonal antibody (Ferrara et al., 2004).”
BackgroundTumor angiogenesis: past, present and the near future
Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 976
Claesson‐Welsh, L., & Welsh, M. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12019 · Cited by 868
FGF Receptors: Cancer Biology and Therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS
Katoh, M., & Nakagama, H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21288 · Cited by 610
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
Zhao, Y., & Adjei, A. A. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0465 · Cited by 558
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
Broad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El-Rayes, B., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 464
Adnane, L., Trail, P. A., Taylor, I., & Wilhelm, S. M. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(05)07047-3 · Cited by 463
Nissen, L. J., Cao, R., Hedlund, E.-M., Wang, Z., Zhao, X., Wetterskog, D., Funa, K., Bråkenhielm, E., & Cao, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32479 · Cited by 290
The multifaceted activity of VEGF in angiogenesis – Implications for therapy responses
Moens, S., Goveia, J., Stapor, P. C., Cantelmo, A. R., & Carmeliet, P. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.009 · Cited by 159
Taeger, J., Moser, C., Hellerbrand, C., Mycielska, M. E., Glockzin, G., Schlitt, H. J., Geissler, E. K., Stoeltzing, O., & Lang, S. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0312 · Cited by 148
Sun, J., Wang, D.-A., Jain, R. K., Carie, A., Paquette, S., Ennis, E., Blaskovich, M. A., Baldini, L., Coppola, D., Hamilton, A. D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208391 · Cited by 108
Mésange, P., Poindessous, V., Sabbah, M., Escargueil, A. E., de Gramont, A., & Larsen, A. K. (2014) · Oncotarget · doi:10.18632/oncotarget.1671 · Cited by 95
Lu, N., Gao, Y., Ling, Y., Chen, Y., Yang, Y., Gu, H.-Y., Qi, Q., Liu, W., Wang, X., You, Q., et al. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.02.013 · Cited by 94
Self-citationChinchar, E., Makey, K. L., Gibson, J., Chen, F., Cole, S. A., MEGASON, G. C., Vijayakumar, S., Miele, L., & Gu, J. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-12 · Cited by 82
Neuraminidase-1: A novel therapeutic target in multistage tumorigenesis
Haxho, F., Neufeld, R. J., & Szewczuk, M. R. (2016) · Oncotarget · doi:10.18632/oncotarget.8396 · Cited by 80
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model
Trédan, O., Lacroix‐Triki, M., Guiu, S., Mouret‐Reynier, M., Barrière, J., Bidard, F., Braccini, A.-L., Mir, O., Villanueva, C., & Barthélémy, P. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0334-9 · Cited by 42
Koyama, S., Takagi, H., Otani, A., Suzuma, K., Nishimura, K., & Honda, Y. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702564 · Cited by 35
Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents
Wang, J., Zhang, L., Pan, X., Dai, B., Sun, Y., Li, C., & Zhang, J. (2017) · Scientific Reports · doi:10.1038/srep45145 · Cited by 24
Shochet, G. E., Israeli‐Shani, L., Koslow, M., & Shitrit, D. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.03.013 · Cited by 15
Cited by
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Shen, G., Zheng, F., Ren, D., Du, F., Dong, Q., Wang, Z., Zhao, F., Ahmad, R., & Zhao, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0664-7 · Cited by 658
Han, B., Li, K., Wang, Q., Zhang, L., Shi, J., Wang, Z., Cheng, Y., He, J., Shi, Y., Zhao, Y., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3039 · Cited by 614
Fibroblast growth factor receptors as treatment targets in clinical oncology
Katoh, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0115-y · Cited by 352
Anlotinib: First Global Approval
Syed, Y. Y. (2018) · Drugs · doi:10.1007/s40265-018-0939-x · Cited by 268
Liang, L., Hui, K., Hu, C., Wen, Y., Yang, S., Zhu, P., Wang, L., Xia, Y., Qiao, Y., Sun, W., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1093-3 · Cited by 187
Metadata
- Authors
- Lin, B., Song, X., Yang, D., Bai, D., Yao, Y., & Lu, N.
- Venue
- Gene
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 654
- Pages
- 77-86
- ISSN
- 0378-1119 (ISSN-L)
- OpenAlex
- W2793605704
- Cited by
- 384
- References
- 22
- FWCI
- 11.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.